Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods

• US 20060258841A1
• Filed: 01/16/2004
• Published: 11/16/2006
• Est. Priority Date: 01/17/2003
• Status: Abandoned Application

• Current Assignee: The Research Foundation for The State University of New York (State University of New York)
• Original Assignee: The Research Foundation for The State University of New York (State University of New York)
• Inventors: Michl, Josef, Hannan, Raquib, Bradu, Stefan M., Pincus, Matthew R.
• Application Number:
  US10/542,239
• Publication Number:
  US 20060258841A1
• Time in Patent Office: Days
• US Class Current: 530/350
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 47/6817 Toxins
• CPC Class Codes: A61K 47/6859 the tumour determinant being from liver or pancreas cancer cell
• CPC Class Codes: A61K 51/1057 the tumor cell being from liver or pancreas
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 16/303 Liver or Pancreas
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/734 Complement-dependent cytotoxicity [CDC]
• CPC Class Codes: G01N 2333/705 Assays involving receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: G01N 33/57438 of liver, pancreas or kidney

Abstract

The present invention is directed to an antigen found on the surface of rat and human pancreatic cancer cells and provides antibodies of high specificity and selectivity to this antigen as well as hybridomas secreting the subject antibodies. Methods for both the diagnosis and treatment of pancreatic cancer are also provided. This tissue marker of pancreatic adenocarcinoma, an approximately 43.5 kD surface membrane protein designated PaCa-Ag1, is completely unexpressed in normal pancreas but abundantly expressed in pancreatic carcinoma cells. Moreover, a soluble form of PaCa-Ag1 exists, having a molecular weight about 36 to about 38 kD, that is readily identified in sera and other body fluids of pancreatic cancer patients, using a subject antibody.

Claims

1. A pancreatic carcinoma-specific antigen 3C4-Ag in substantially purified form characterized by:

a molecular weight of about 43.5 kDa as determined by SDS-PAGE;

a pI on isoelectrofocusing of about 4.5 to about 5.0;

being unglycosylated or minimally glycosylated; and

being primarily localized on the surface of rat and human pancreatic cancer cells but not detected in normal, non-proliferating cells.

3. An immunologically active fragment of the pancreatic carcinoma-specific antigen 3C4-Ag of claim 1.

8. A murine hybridoma cell line which produces a monoclonal antibody specifically immunoreactive with the 3C4-Ag antigen of claim 1 or 2.

2. A soluble pancreatic carcinoma-specific antigen 3C4-Ag having a molecular weight of about 36 to about 38 kD as determined by SDS-PAGE and isolatable from sera and other bodily fluids of pancreatic cancer patients.

4. An antibody or binding portion thereof, having binding specificity to pancreatic carcinoma specific antigen 3C4-Ag, wherein said antigen is characterized by:

a molecular weight of about 43 kDa as determined by SDS-PAGE;

a pI on isoelectrofocusing of about 4.5 to about 5.0;

being unglycosylated or minimally glycosylated; and

being primarily localized on the surface of rat and human pancreatic cancer cells but not detected in normal, non-proliferating cells.

5. The antibody of binding portion thereof, of claim 4 which also binds to a soluble pancreatic carcinoma-specific antigen having a molecular weight of about 36 to about 38 kD as determined by SDS-PAGE and isolatable from sera and other bodily fluids of pancreatic cancer patients.

6. The antibody of claim 4 or 5 which is a polyclonal antibody.

7. The antibody of claim 4 or 5 which is a monoclonal antibody.

9. A murine hybridoma cell line which produces the monoclonal antibody of claim 4.

10. A monoclonal antibody, mAb34C, secreted by the hybridoma cell line of claim 9.

11. The monoclonal antibody mAb3C4 of claim 7 or 10 in a humanized form.

12. An antibody according to claim 4 or 5 wherein the antibody is labeled with a fluorophore, chemilophore, chemiluminecer, photosensitizer, suspended particles, radioisotope or enzyme.

13. An antibody according to claim 10 wherein the antibody is labeled with a fluorophore, chemilophore, chemiluminecer, photosensitizer, suspended particles, radioisotope or enzyme.

14. An antibody according to claim 4 or 5 wherein the antibody is conjugated or linked to a therapeutic drug or toxin.

15. The antibody of claim 14 wherein the therapeutic drug or toxin is a peptide at least about six contiguous amino acids of the amino sequence set forth in SEQ PPLSQETFSDLWKLL (SEQ ID NO:

1) or an analog or derivative thereof.

16. The antibody of claim 15 wherein the penetratin sequence from antennapedia protein having the amino acid sequence KKWKMRRNQFWVKVQRG (SEQ ID NO:

4) is positioned at the carboxy terminal end of the peptide.

17. An antibody according to claim 10 wherein the antibody is conjugated or linked to a therapeutic drug or toxin.

18. A method of detecting pancreatic cancer in an animal subject, said method comprising the steps of:

(a) contacting a cell, tissue or fluid sample from the subject with at least one of an antibody or binding portion thereof which specifically binds to 3C4-Ag or an immunologically active fragment thereof;

the monoclonal antibody mAb34C;

or an antibody which binds the epitope bound by the monoclonal antibody mAb34C;

under conditions permitting said antibody to specifically bind an antigen in the sample to form an antibody-antigen complex;

(b) detecting antibody-antigen complex in the sample; and

(c) correlating the detection of elevated levels of antibody-antigen complex in the sample with the presence of pancreatic cancer.

19. A diagnostic kit suitable for detecting 3C4-Ag in a cell, tissue, or fluid sample from a patient, said kit comprising:

(a) an antibody or binding portion thereof which specifically binds 3C4-Ag or an immunologically active fragment thereof,

(b) a conjugate of a specific binding partner for-the-antibody or binding portion thereof; and

(c) a label for detecting the bound antibody.

20. A method of treating pancreatic cancer in a patient suffering therefrom which comprises administering to the patient an effective amount of an antibody or binding portion thereof which specifically binds to 3C4-Ag or an immunologically active fragment thereof, wherein said antibody or binding portion thereof is conjugated or linked to a therapeutic drug or toxin.

21. The method of claim 20 wherein said antibody is mAb3C4.

22. The method of claim 20 or 21 wherein the therapeutic drug or toxin is a peptide of at least about six contiguous amino acids of the amino sequence set forth in SEQ PPLSQETFSDLWKLL (SEQ ID NO:

1) or an analog or derivative thereof.

23. A pharmaceutical composition comprising an antibody or binding portion thereof which specifically binds to 3C4-Ag, admixed with a pharmaceutically acceptable carrier.

24. The pharmaceutical composition of claim 23 wherein the antibody or binding portion thereof which specifically binds to 3C4-Ag is conjugated or linked to a therapeutic drug or toxin.